Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

May 22, 2020

Primary Completion Date

December 29, 2020

Study Completion Date

April 9, 2021

Conditions
COVID-19
Interventions
DRUG

Zilucoplan®

14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan®

DRUG

Placebo

standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)

Trial Locations (9)

1070

Erasmus University Hospital, Brussels

3700

AZ Vesalius, Tongeren

4000

University Hospital Liège, Liège

8000

AZ Sint Jan Brugge, Bruges

8800

AZ Delta, Roeselare

9000

AZ Sint-Lucas, Ghent

University Hospital Ghent, Ghent

9300

OLVZ Aalst, Aalst

128900

Jan Yperman Ziekenhuis Ieper, Ieper

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

University Hospital, Ghent

OTHER